CRISPR Therapeutics AG (NASDAQ:CRSP) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. BofA is Bullish on CRISPR Therapeutics AG (CRSP) On January 22, 2026, TheFly disclosed that Alec Stranahan, a BofA analyst. It reduced the price objective for CRISPR Therapeutics AG (NASDAQ:CRSP) from $90 to $89 and retained a buy rating. Casgevy’s 2026 projections were slightly lowered as a result of the modification. Based on an earnings preview paper covering the biotechnology group, BofA still pro ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP) , has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.The company, which often features at the top of several funds managed by Cathie Wood’s Ark Invest, such as the Ark Innovation ETF (BATS:ARKK) and the Ark Genomic Revolution ETF (BATS:ARKG) , is seeing its Momentum score slide over the past couple of days.Biotech Stock Sees Momentum SlideThe Momentum score ...

CEO Samarth Kulkarni sold 60,000 shares, impacting CRISPR Therapeutics AG's (NASDAQ:CRSP) stock performance.The stock experienced a 4.71% decline recently, contrasting with the broader market's gains.Upcoming earnings report expected to show a significant decrease in EPS and revenue, highlighting financial challenges.CRISPR Therapeutics AG (NASDAQ:CRSP) is a biotechnology company focused on developing transformative gene-based medicines. The company is a leader in CRISPR/Cas9 gene-editing technology, which ...

Core Viewpoint - Concerns about an AI bubble may lead to a slowdown in market gains, but Cathie Wood believes a "Golden Age" for markets is possible in the next three years due to a favorable business environment under the Trump administration [1][6]. Economic Projections - Wood predicts that falling interest rates, tax cuts, and deregulation, which she describes as "Reaganomics on steroids," could result in U.S. GDP growth accelerating to 6% to 8% annually in the coming years [2]. Investment Focus - Cathie Wood's investment strategy emphasizes companies that are at the forefront of industry-disrupting innovations, particularly in technology, which has garnered her a significant following in the tech investment community [3]. - Heavy capital spending by major U.S. companies is expected to lead to productivity boosts driven by technological advancements, including AI, with operational costs for running models anticipated to decline [3]. Technological Developments - Advancements in AI, robotics, energy storage, blockchain, and biological technology are expected to drive productivity growth to new sustainable highs and create significant wealth [4]. Market Outlook - Wood's outlook for 2026 is more optimistic than many Wall Street analysts, who expect more modest gains for the S&P 500 compared to last year, although she did not provide a specific target for the index [4]. Performance of ARK Innovation ETF - The ARK Innovation ETF (ARKK), which includes major holdings like Tesla, Crispr Therapeutics, Roku, and Coinbase, achieved a total return of approximately 35% last year, outperforming the S&P 500's 18% return [5].

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $54.21, marking a -4.71% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%. Prior to today's trading, shares of the company had gained 3.93% outpaced the Medical sector's gain of 0.92% and the S&P 500's gain of 1.57%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming ea ...

Core Insights - The individual has extensive experience in finance, having worked as a Senior Manager at a Big Four accounting firm and as a CFO for two privately held companies in the aerospace and defense and beauty industries [1] - The investment philosophy leans towards value investing, particularly favoring the Buffett/Munger approach of acquiring quality businesses at fair prices while remaining open to various investment ideas [1] - Emphasis is placed on thorough research and continuous monitoring of investments, including quarterly financial reviews and staying updated with relevant news [1] Company Insights - The companies involved have sales ranging from $50 million to $100 million, indicating a focus on mid-sized enterprises within their respective industries [1] - The aerospace and defense sector, along with the beauty industry, are highlighted as key areas of investment interest, suggesting potential growth opportunities in these markets [1] Investment Strategy - The strategy involves a long-term holding approach, with a preference for reinvesting dividends rather than frequent trading, which aligns with a value investing mindset [1] - Acknowledgment of both positive aspects and risks associated with investments is crucial, as it reflects a balanced perspective on market dynamics [1]

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

Core Insights - CRISPR Therapeutics is focused on transforming medicine through gene editing, with significant progress across four franchises [2] - The company has an approved product, CASGEVY, in collaboration with Vertex, which has multibillion-dollar revenue potential and is expanding its addressable population [2] - Ongoing efforts in in vivo gene editing aim to improve access for patients with sickle cell disease [2] Franchise Developments - The company has made advancements in its in vivo platform, particularly in gene editing of the liver [3] - Transformative data for CTX310 related to hypercholesterolemia was published in November of the previous year [3] - A partnership has been established to enhance the company's RNA platform, indicating a strategic expansion of capabilities [3]

Summary of CRISPR Therapeutics FY Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: FY Conference Call on January 12, 2026 - **Focus**: Progress and updates on gene editing technologies and therapies Key Points Industry and Market Position - CRISPR Therapeutics is focused on transforming medicine through gene editing, aiming to develop cures for serious diseases [2][34] - The company has made significant advancements across four franchises, including hemoglobinopathies, in vivo gene editing, CAR-T therapies, and RNA-based therapies [2][3] Hemoglobinopathies - **Casgevy**: An approved product with multi-billion dollar revenue potential, showing a 3x increase in patient initiation and cell collections from 2024 to 2025 [5][6] - Revenue surpassed $100 million, with positive payer coverage in the U.S. and Europe [5][6] - Pediatric data for sickle cell and thalassemia shows promising results, expanding the addressable patient population [6][7] In Vivo Gene Editing - Focus on in vivo gene editing of the liver, with promising data for CTX310 targeting hypercholesterolemia [3][11] - A single infusion can lead to a nearly 50% reduction in LDL cholesterol and a 55% reduction in triglycerides [14][15] - The potential for a multi-billion dollar opportunity in treating cardiovascular diseases [17] CAR-T Therapies - CTX112 shows a 70% complete response rate in oncology settings, with a favorable safety profile [27][28] - The company is exploring maintenance therapies to enhance durability of responses [28] - In vivo CAR-T approaches are being developed, utilizing proprietary lipid nanoparticle systems [30] RNA-Based Therapies - CTX611 targets Factor XI, with a potential to revolutionize anticoagulation therapy, showing a 93% reduction in Factor XI antigen levels [21][23] - The siRNA market is projected to be a $20 billion opportunity, with CRISPR's approach aiming to reduce bleeding risks associated with current therapies [21][24] Regulatory and Future Outlook - The FDA is supportive of gene editing technologies, which may facilitate smoother regulatory pathways for CRISPR's programs [40][41] - The company anticipates pivotal trials for several programs, including A1AT and CTX310, in the coming years [36][39] - Continuous innovation and partnerships are expected to enhance the development of their pipeline [47][48] Financial Considerations - CRISPR aims to reduce healthcare costs through one-time gene editing solutions, potentially pricing therapies below $100,000 [50] - The company is focused on creating pharmacoeconomic benefits through its innovative therapies [50] Societal Impact and Diversity - The company acknowledges the importance of addressing racial and ethnic differences in treatment responses, particularly in hypertension medications [51] AI Integration - AI is being utilized to enhance efficiency in clinical trials and improve gene editing processes, particularly in protein and mRNA design [53] Conclusion - CRISPR Therapeutics is positioned for significant growth with a diverse pipeline of innovative therapies across multiple disease areas, supported by strong market potential and favorable regulatory conditions. The company is committed to continuous innovation and addressing healthcare affordability through its gene editing technologies [34][56]

CRISPR Corporate Update 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 1 Forward-Looking Statements This presentation and related materials may contain statements regarding matters that are not historical facts and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Suc ...